[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626483":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":11,"centralContacts":39,"locations":45,"responsibleParty":65,"collaborators":11,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":11,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":11,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":11,"overallStatus":86,"whyStopped":11,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Akeso","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"AK139 regimen 1","EXPERIMENTAL",null,[13],"Drug: AK139",{"label":15,"type":10,"description":11,"interventionNames":16},"AK139 regimen 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"AK139 regimen 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Placebo",[23],"Drug: Placebo",[25,30,33,36],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"DRUG","AK139","AK139 regimen 1- subcutaneous injection.",[9],{"type":26,"name":27,"description":31,"armGroupLabels":32,"otherNames":11},"AK139 regimen 2- subcutaneous injection.",[15],{"type":26,"name":27,"description":34,"armGroupLabels":35,"otherNames":11},"AK139 regimen 3- subcutaneous injection.",[18],{"type":26,"name":21,"description":37,"armGroupLabels":38,"otherNames":11},"subcutaneous injection.",[21],[40],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"Guoqin Wang","CONTACT","+86 (0760) 8987 399","global.trials@akesobio.com",[46,57],{"facility":47,"status":11,"city":48,"state":11,"zip":11,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":11},"The First Affiliated Hospital of Guangzhou Medical University","Guangzhou","China","CN",{"type":52,"coordinates":53},"Point",[54,55],113.25,23.11667,{"lat":55,"lon":54},{"facility":58,"status":11,"city":59,"state":11,"zip":11,"country":49,"countryCode":50,"cosmosGeoPoint":60,"geoPoint":64,"contacts":11},"Shanghai General Hospital","Shanghai",{"type":52,"coordinates":61},[62,63],121.45806,31.22222,{"lat":63,"lon":62},{"type":66,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100626483","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-ak139-in-participants-with-asthma-100626483",false,"NCT07436221","A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma","A Randomized, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of AK139 in the Treatment of Participants With Moderate to Severe Asthma","Inclusion Criteria:\n\n1. Diagnosed with asthma at least one year;\n2. Evidence of the reversibility of airflow limitation meets the requirements of the protocol;\n3. Pre-bronchodilator forced expiratory volume (FEV1) meets the requirements of the protocol at screening and baseline;\n4. Asthma Control Questionnaire 5-question version (ACQ-5) score≥1.5 at screening and baseline;\n5. The participants agree to use highly effective contraception methods from the moment of signing of the ICF to 3 months after the last dose of the investigational product.\n\nExclusion Criteria:\n\n1. Concomitant respiratory diseases that, as determined by investigators, may affect the evaluation of therapeutic effects or safety of the investigational product;\n2. A participant who experiences a severe asthma exacerbation at any time from 4 weeks prior to the screening up to and including the baseline;\n3. Allergic to any component of the investigational product or intolerant to basis treatment;\n4. Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to;\n5. Other reasons the investigators believe that the participants are not suitable to enrolled in this study.","ALL","18 Years","65 Years",{"count":78,"type":79},160,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe asthma.",[85],"Asthma","NOT_YET_RECRUITING","2026-02-25",{"date":89,"type":90},"2026-02-27","ACTUAL",{"date":92,"type":79},"2026-02-28",{"date":94,"type":79},"2027-02-26",{"name":5,"class":6},2]